DL-β-Amino-α-tosylamino-propionsaeure | 24571-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: DL-β-Amino-α-tosylamino-propionsaeure
• 英文别名: 3-Amino-2-p-toluolsulfonylamino-propionsaeure；2(S)-(p-Toluenesulfonylamino)-3-aminopropionic acid；2(S)-Tosylamino-3-aminopropionic acid；3-Azaniumyl-2-[(4-methylphenyl)sulfonylamino]propanoate
• CAS: 24571-53-7
• 化学式: C₁₀H₁₄N₂O₄S
• mdl: MFCD00129854
• 分子量: 258.298
• InChiKey: NOFBBVASBDIESZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-Tosyl-L-Asparagine 在 sodium hydroxide 、 溴 作用下， 以 水 为溶剂， 生成 DL-β-Amino-α-tosylamino-propionsaeure
  参考文献：
  名称：

  Fibrinogen receptor antagonists

  摘要：

  该发明的化合物具有以下结构式 ##STR1## 这些化合物具有纤维蛋白原受体拮抗活性。

  公开号：

  US05821241A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE)<br/>[FR] COMPOSES HETEROCYCLIQUES BLOQUANT LES EFFETS DES PRODUITS TERMINAUX AVANCES DE GLYCATION
  申请人：REDDYS LAB LTD DR

  公开号：WO2005040163A1

  公开（公告）日：2005-05-06

  The present invention relates to novel compounds of Formula (Ia) or (Ib), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. Formula (Ia), or Formula (Ib) in the above formulae L represents Formula (I), Formula (II) or -(CH2)1- Q represents Formula (III), or Formula (IV). The present invention also relates to a process for the preparation of the above said novel compounds, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory responses in tissues, including endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. The present invention also relates to compounds that act as modulators of Perlecan activity and expression. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPG) such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as stenosis, restenosis, neointimal hyperplasia, and atherosclerosis. The compounds of Formula (I) are also useful for the treatment and/or prevention of cancer. The types of cancers include melanoma, prostate, leukemia, lymphoma, non-small lung cancers, cancer of the central nervous system, breast, colon, ovarian or renal cancer.

  本发明涉及公式（Ia）或（Ib）的新化合物，它们的药学上可接受的盐以及含有它们的药学上可接受的组合物。在上述公式中，公式（Ia）或公式（Ib）中的L代表公式（I）、公式（II）或-(CH2)1-，Q代表公式（III）或公式（IV）。本发明还涉及制备上述新化合物、其药学上可接受的盐和含有它们的药物组合物的方法。本发明还涉及包括治疗由炎症反应引起的病理生理条件的化合物的方法和组合物。具体而言，本发明涉及抑制或阻断组织中糖化蛋白诱导的与信号相关的炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。本发明还涉及作为Perlecan活性和表达调节剂的化合物。具体而言，本发明涉及通过调节肝素硫酸蛋白聚糖（HSPG）如Perlecan来抑制平滑肌细胞增殖的化合物。本发明进一步涉及利用化合物治疗由平滑肌增殖特征的血管闭塞性疾病，如狭窄、再狭窄、新内膜增生和动脉粥样硬化。公式（I）的化合物也可用于治疗和/或预防癌症。癌症类型包括黑色素瘤、前列腺癌、白血病、淋巴瘤、非小细胞肺癌、中枢神经系统癌症、乳腺癌、结肠癌、卵巢癌或肾癌。
• Heterocyclic compounds and methods of making and using thereof
  申请人：Rao Koteswar Yeleswarapu

  公开号：US20050119269A1

  公开（公告）日：2005-06-02

  Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided.

  提供化学式(I)的化合物，以及包含这些化合物的方法和/或组合物，这些化合物对调节由AGE和糖基化蛋白堆积引起的炎症反应有效。还提供了有效调节平滑肌细胞增殖及其相关疾病或病况的方法和/或组合物。
• Integrin receptor antagonists
  申请人：——

  公开号：US20020010176A1

  公开（公告）日：2002-01-24

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

  本发明涉及化合物及其衍生物，其合成以及它们作为整合素受体拮抗剂的用途。更具体地说，本发明的化合物是整合素受体αvβ3、αvβ5和/或αvβ6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。
• Hemostatic and platelet increasing agent containing alpha, beta-diaminopropionic acid and derivatives thereof
  申请人：Hokuriku Pharmaceutical Co.,Ltd

  公开号：EP0009728A1

  公开（公告）日：1980-04-16

  Hemostatic and platelet increasing agent composition comprising α,β-diaminopropionic acid and derivatives thereof represented by the formula: wherein R1, and R2 each represent a hydrogen atom, an acyl group, a benzyl group or a substituted sulfonyl group, and pharmaceutical acceptable salts thereof.

  止血剂和血小板增加剂组合物，包括α,β-二氨基丙酸及其由式表示的衍生物： 其中 R1 和 R2 分别代表氢原子、酰基、苄基或取代的磺酰基，以及它们的药用盐。
• FIBRINOGEN RECEPTOR ANTAGONISTS
  申请人：MERCK & CO., INC.

  公开号：EP0866705A1

  公开（公告）日：1998-09-30